Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says

MT Newswires Live

昨天

Verastem's (VSTM) shares are not fully valuing its growth potential, considering a "major upcoming catalyst" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.

Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.

RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.

Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.

RBC has an outperform speculative risk rating on the stock and a $14 price target.

Price: 7.65, Change: +0.10, Percent Change: +1.32

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2668092484"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2668092484\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2668092484?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 22:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668092484","market":"hk","top_or_hot":-1,"title":"Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.</p><p>Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.</p><p>RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.</p><p>Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.</p><p>RBC has an outperform speculative risk rating on the stock and a $14 price target.</p><p>Price: 7.65, Change: +0.10, Percent Change: +1.32</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem's Shares Not Fully Valuing its Growth Potential, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-18 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.</p><p>Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.</p><p>RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.</p><p>Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.</p><p>RBC has an outperform speculative risk rating on the stock and a $14 price target.</p><p>Price: 7.65, Change: +0.10, Percent Change: +1.32</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668092484","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668092484","pubTimestamp":1789743079,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verastem's  shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.RBC has an outperform speculative risk rating on the stock and a $14 price target.Price: 7.65, Change: +0.10, Percent Change: +1.32","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VSTM":"Verastem"},"translate_title":"加拿大皇家银行表示，Verastem 的股票并未充分发挥其增长潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1.5},"content_text":"Verastem's (VSTM) shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.RBC has an outperform speculative risk rating on the stock and a $14 price target.Price: 7.65, Change: +0.10, Percent Change: +1.32","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}